Both groups showed reduced cannabis use at follow-up , with no advantage of nabiximols over placebo for self-reported cannabis use ( F@ ,@ = @ ; P = @ ) , cannabis-related problems ( F@ ,@ = @ ; P = @ ) , or cannabis dependence ( F@ ,@ < @ ; P = @ ) .